Molecular Partners AG
c/o Department of Biochemistry
81 articles with Molecular Partners AG
All development and commercialization rights for MP0310, a clinical stage immunomodulator intended to treat solid tumors, will be reverted to Molecular Partners.
The EUA request is based on the Phase II study that showed treatment with ensovibep reduced the viral load from the SARS-CoV-2 virus within eight days of use compared to placebo.
Clinical Catch-Up: January 10-14
1/17/2022Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
The U.S. averages more than 700,000 new COVID-19 cases per day. As of Saturday, there were 4.91M cases, more cases in seven days than in April, May, June, and July 2021 combined.
Clinical Catch-Up: December 6-10
12/13/2021There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
AbbVie’s Allergan Aesthetics announced it was buying Soliton in a deal worth about $550 million. Now, the Federal Trade Commission has requested additional information about the deal.
AbbVie has terminated its license and collaboration deal with Molecular Partners for abicipar pegol, and returned all rights to the Swiss company. Here's more about it.
Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million.
Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep
Molecular Partners AG announced that the first patient has been dosed in a new Phase 3 sub-study evaluating ensovibep, as part of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership designed to speed development of treatments and vaccine candidates for COVID-19.
Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States
Molecular Partners AG today announced that it has commenced an initial public offering in the United States of 3,000,000 American Depositary Shares.
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization
Molecular Partners' COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants In Vitro
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced results from parallel laboratory studies conducted in collaboration with academic and government partners in Switzerland and the United States.
Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced its interim management statement for the period ending March 31, 2021.
2021 COVID-19 News: COVID-19 Possible Spread in Vehicles, US to Share AZ's COVID-19 Vaccine Globa...
4/27/2021Please check out the biopharma industry's COVID-19 stories that are trending for April 27, 2021.
Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, representing common shares, in the United States.
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company's work in the development of protein-based treatments for COVID-19 and various cancers.
Shareholders of Molecular Partners AG Approve all Board Proposals at the Annual General Meeting; Agnete Fredriksen and Dominik Höchli Elected New Board Members
At todays AGM of Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, the shareholders of the company approved all motions proposed by the Board of Directors with a very large majority.
Clinical Catch-Up: April 5-9
4/12/2021It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR
Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the presentation of four posters highlighting research across its immuno-oncology programs at the American Association for Cancer Research virtual Annual Meeting.